Mavyret scripts for week ending 9/8/17 (from IMS)… TRx: 185, +29% from prior week NRx: 156, +14% from prior week The market seems to like these numbers. Note: Mavyret’s absolute script figures reported by IMS are low because IMS misses much of the public sector of the HCV market that ABBV is targeting.